GeoPark Reports Third Quarter 2023 Results
Exploration Successes Open Multiple Growth Fairways, Drilling Opportunities & New Plays Consistently Strong Free Cash Flow BOGOTA, Colombia–(BUSINESS WIRE)–GeoPark... Read more.
GeoPark Announces Quarterly Cash Dividend of $0.134 Per Share and Renewal of Share Repurchase Program
BOGOTA, Colombia–(BUSINESS WIRE)–GeoPark Limited (“GeoPark” or the “Company”) (NYSE: GPRK), a leading independent Latin American oil and gas... Read more.
IDEX Corporation Declares Regular Quarterly Cash Dividend
NORTHBROOK, Ill.–(BUSINESS WIRE)–IDEX CORPORATION (NYSE:IEX) today announced that its Board of Directors has approved a regular quarterly cash dividend... Read more.
Summer Announces Combined $68M in Series A Round and Debt Facility to Innovate New Approach to Vacation Homeownership
Summer completes an $18M Series A round led by QED Investors and Viola FinTech, and secures a debt facility of up to $50M from Setpoint Capital NEW YORK–(BUSINESS... Read more.
Dun & Bradstreet and Databricks Launch New DUNSified™ Data Marketplace
Alliance creates the industry’s first data marketplace of Dun & Bradstreet and third-party data JACKSONVILLE, Fla.–(BUSINESS WIRE)–Dun & Bradstreet... Read more.
Ziff Davis Reports Third Quarter 2023 Financial Results and Reaffirms 2023 Guidance
NEW YORK–(BUSINESS WIRE)–Ziff Davis, Inc. (NASDAQ: ZD) (“Ziff Davis” or “the Company”) today reported unaudited financial results for the third... Read more.
Takeda Receives U.S. FDA Approval of FRUZAQLA™ (fruquintinib) for Previously Treated Metastatic Colorectal Cancer
− FRUZAQLA is the First Targeted Therapy Approved for Metastatic Colorectal Cancer (mCRC) Regardless of Biomarker Status or Prior Types of Therapies in More Than... Read more.
DXP Enterprises, Inc. Reports Third Quarter 2023 Results
$27.2 million in cash $419.2 million in sales, an 8.2 percent year-over-year increase $1,271.6 million in year to date sales, an 18.3 percent year-over-year increase... Read more.
Atara Biotherapeutics Announces Primary Analysis Data from Phase 2 EMBOLD Clinical Trial of ATA188 in Non-Active Progressive Multiple Sclerosis
Primary Endpoint of Confirmed Disability Improvement at 12 Months Not Achieved Company to Further Analyze Data and Evaluate Strategic Options for ATA188 Program... Read more.
Medidata Announces New Data Integration Solutions to Accelerate Clinical Trials: Clinical Data Studio and Health Record Connect
Adding to Medidata’s already extensive platform, Medidata Clinical Data Studio and Medidata Health Record Connect usher in a new era of data integration and management... Read more.